NCT00783653已完成1 期
Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 5
- 主要终点
- Definition of a recommended Phase III dose and determination CTC version 3.0 grade 3-5 non-hematological toxicities of SU11248 in combination with standard induction and consolidation chemotherapy
研究概览
简要总结
In this study safety and tolerability of two dose levels of SU 11248 (sutent) with standard chemotherapy in patients with FLT3 mutated AML over 60 years will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with primary or secondary acute myeloid leukemia (any FAB type, except M3).
- •No prior systemic chemotherapy for AML except hydroxyurea. Cytoreductive therapy with hydroxyurea is recommended if WBC is > 50.000/µl, but should cease at least one day prior to starting study medication
- •Patient age equal or of greater than 60 years
- •Patients must have FLT3 mutated AML, either ITD or kinase domain mutations
- •ECOG Performance score 3 or less (Karnofsky Performance Score >40%).
- •Life expectancy more than four weeks.
- •Adequate hepatic and renal function, as defined by serum transaminases <2.5x ULN, bilirubin <1.5x ULN. Creatinine <1.5x ULN.
- •Patients must provide written informed consent to participate in the trial.
- •Normal heart function on cardiac ultrasound
- •Prothrombin time (PT) and partial thromboplastin time (PTT) <=1.5 x ULN
- •Serum albumin >=3.0 g/dl
- •Serum amylase and lipase <=1.0 x ULN
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
排除标准
- •The presence of any of the following will exclude a subject from study enrollment:
- •Treatment with any investigational agent within four weeks.
- •Known HIV infection
- •Presence of any medical or psychiatric condition which may limit full compliance with the study, including but not limited to:
- •Presence of CNS leukaemia
- •Unresolved toxicity from previous anti-cancer therapy or incomplete recovery from surgery.
- •Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.
- •Current treatment with therapeutic doses of anticoagulant (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
- •Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
- •Pre existing thyroid abnormality of thyroid function that cannot be maintained in the normal range with medication.
- •Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2, atrial fibrillation of any Grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
- •Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
结局指标
主要结局
Definition of a recommended Phase III dose and determination CTC version 3.0 grade 3-5 non-hematological toxicities of SU11248 in combination with standard induction and consolidation chemotherapy
时间窗: April 2011
次要结局
- Objective tumor response, as defined using the revised recommendations of the International Working Group for diagnosis, standardization of response criteria in Acute Myeloid Leukemia for AML(April 2011)
- Overall safety profile of SU11248 characterized by type, frequency, severity (graded using NCI CTCAE Version 3.0), timing and relatedness of adverse events (AEs) and laboratory(April 2011)
研究者
研究点 (5)
Loading locations...
相似试验
终止
1 期
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal CancerColorectal CarcinomaNCT00361244Massachusetts General Hospital6
进行中（未招募）
不适用
Phase I/II Clinical Study of SU11248 (Sutent) combined with Standard Chemotherapy with Cytosine Arabinoside and Daunorubicin in Patients with FLT3 mutated AML over 60 years of ageMedDRA version: 14.1Level: LLTClassification code 10001941Term: AMLSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Acute Myeloid LeukemiaEUCTR2007-007553-31-DEniversity Medical Center Hamburg-Eppendorf30
已完成
2 期
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain MetastasesNon-Small Cell Lung CancerNCT00372775Pfizer66
已完成
1 期
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid TumorsNeoplasmsNCT00528619Pfizer96
已完成
1 期
Study Of Sunitinib Plus FOLFOX In Patients With Solid TumorsNeoplasmsColorectal NeoplasmsNCT00599924Pfizer53